用于治疗肺动脉高压的5型磷酸二酯酶抑制剂。 - Suppr

Suppr

超能文献

Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension.

作者信息

Archer Stephen L, Michelakis Evangelos D

机构信息

Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.

出版信息

N Engl J Med. 2009 Nov 5;361(19):1864-71. doi: 10.1056/NEJMct0904473.

DOI:10.1056/NEJMct0904473

PMID:19890129

Abstract

摘要

相似文献

Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension.

N Engl J Med. 2009 Nov 5;361(19):1864-71. doi: 10.1056/NEJMct0904473.

Phosphodiesterase inhibitors for pulmonary hypertension.

N Engl J Med. 2010 Feb 11;362(6):559-60; author reply 560.

Phosphodiesterase inhibitors for pulmonary hypertension.

N Engl J Med. 2010 Feb 11;362(6):559; author reply 560. doi: 10.1056/NEJMc0912127.

Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.

Adv Ther. 2009 Sep;26(9):813-25. doi: 10.1007/s12325-009-0064-z. Epub 2009 Sep 19.

Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension.

Circulation. 2010 Jul 6;122(1):88-95. doi: 10.1161/CIRCULATIONAHA.110.944603.

Preoperative administration of PDE-5 Inhibitors.

J Clin Anesth. 2009 Mar;21(2):149; author reply 149-50. doi: 10.1016/j.jclinane.2009.01.001.

Central retinal vein occlusion in a patient after being commenced on sildenafil citrate for pulmonary arterial hypertension.

Indian J Chest Dis Allied Sci. 2009 Oct-Dec;51(4):249-51.

Phosphodiesterase type 5 inhibition: a support of the left ventricular assist device bridge to transplant.

Circ Heart Fail. 2008 Nov;1(4):211-2. doi: 10.1161/CIRCHEARTFAILURE.108.830570.

[Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].

Dtsch Med Wochenschr. 2006 Dec 8;131(49 Suppl 9):S311-4. doi: 10.1055/s-2006-957199.

Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure.

J Card Fail. 2009 Feb;15(1):31-4. doi: 10.1016/j.cardfail.2008.09.005. Epub 2008 Nov 5.

引用本文的文献

Molecular Dynamics-Assisted Discovery of Novel Phosphodiesterase-5 Inhibitors Targeting a Unique Allosteric Pocket.

Molecules. 2025 Jan 27;30(3):588. doi: 10.3390/molecules30030588.

Portopulmonary Hypertension: An Updated Review.

Transplant Direct. 2023 Jul 21;9(8):e1517. doi: 10.1097/TXD.0000000000001517. eCollection 2023 Aug.

Jagged/Notch proteins promote endothelial-mesenchymal transition-mediated pulmonary arterial hypertension via upregulation of the expression of GATAs.

J Cell Mol Med. 2023 Apr;27(8):1110-1130. doi: 10.1111/jcmm.17723. Epub 2023 Mar 20.

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Eur Respir Rev. 2022 Oct 5;31(166). doi: 10.1183/16000617.0061-2022. Print 2022 Dec 31.

Novel Targets in a High-Altitude Pulmonary Hypertension Rat Model Based on RNA-seq and Proteomics.

Front Med (Lausanne). 2021 Nov 3;8:742436. doi: 10.3389/fmed.2021.742436. eCollection 2021.

Beneficial Extracardiac Effects of Cardiovascular Medications.

Curr Cardiol Rev. 2022;18(2):e151021197270. doi: 10.2174/1573403X17666211015145132.

Nitrosative Stress and Human Disease: Therapeutic Potential of Denitrosylation.

Int J Mol Sci. 2021 Sep 10;22(18):9794. doi: 10.3390/ijms22189794.

PDE9A deficiency does not prevent chronic-hypoxic pulmonary hypertension in mice.

Physiol Rep. 2021 Sep;9(18):e15057. doi: 10.14814/phy2.15057.

Integrated bioinformatic analysis reveals the underlying molecular mechanism of and potential drugs for pulmonary arterial hypertension.

Aging (Albany NY). 2021 May 18;13(10):14234-14257. doi: 10.18632/aging.203040.

The Efficacy and Safety of Pulmonary Vasodilators in Pediatric Pulmonary Hypertension (PH): A Systematic Review and Meta-analysis.

Front Pharmacol. 2021 Apr 23;12:668902. doi: 10.3389/fphar.2021.668902. eCollection 2021.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension.

作者信息

Archer Stephen L, Michelakis Evangelos D

机构信息

Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.

出版信息

N Engl J Med. 2009 Nov 5;361(19):1864-71. doi: 10.1056/NEJMct0904473.

DOI:10.1056/NEJMct0904473

PMID:19890129

Abstract

摘要

相似文献

Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension.

N Engl J Med. 2009 Nov 5;361(19):1864-71. doi: 10.1056/NEJMct0904473.

Phosphodiesterase inhibitors for pulmonary hypertension.

N Engl J Med. 2010 Feb 11;362(6):559-60; author reply 560.

Phosphodiesterase inhibitors for pulmonary hypertension.

N Engl J Med. 2010 Feb 11;362(6):559; author reply 560. doi: 10.1056/NEJMc0912127.

Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.

Adv Ther. 2009 Sep;26(9):813-25. doi: 10.1007/s12325-009-0064-z. Epub 2009 Sep 19.

Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension.

Circulation. 2010 Jul 6;122(1):88-95. doi: 10.1161/CIRCULATIONAHA.110.944603.

Preoperative administration of PDE-5 Inhibitors.

J Clin Anesth. 2009 Mar;21(2):149; author reply 149-50. doi: 10.1016/j.jclinane.2009.01.001.

Central retinal vein occlusion in a patient after being commenced on sildenafil citrate for pulmonary arterial hypertension.

Indian J Chest Dis Allied Sci. 2009 Oct-Dec;51(4):249-51.

Phosphodiesterase type 5 inhibition: a support of the left ventricular assist device bridge to transplant.

Circ Heart Fail. 2008 Nov;1(4):211-2. doi: 10.1161/CIRCHEARTFAILURE.108.830570.

[Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].

Dtsch Med Wochenschr. 2006 Dec 8;131(49 Suppl 9):S311-4. doi: 10.1055/s-2006-957199.

Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure.

J Card Fail. 2009 Feb;15(1):31-4. doi: 10.1016/j.cardfail.2008.09.005. Epub 2008 Nov 5.

引用本文的文献

Molecular Dynamics-Assisted Discovery of Novel Phosphodiesterase-5 Inhibitors Targeting a Unique Allosteric Pocket.

Molecules. 2025 Jan 27;30(3):588. doi: 10.3390/molecules30030588.

Portopulmonary Hypertension: An Updated Review.

Transplant Direct. 2023 Jul 21;9(8):e1517. doi: 10.1097/TXD.0000000000001517. eCollection 2023 Aug.

Jagged/Notch proteins promote endothelial-mesenchymal transition-mediated pulmonary arterial hypertension via upregulation of the expression of GATAs.

J Cell Mol Med. 2023 Apr;27(8):1110-1130. doi: 10.1111/jcmm.17723. Epub 2023 Mar 20.

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Eur Respir Rev. 2022 Oct 5;31(166). doi: 10.1183/16000617.0061-2022. Print 2022 Dec 31.

Novel Targets in a High-Altitude Pulmonary Hypertension Rat Model Based on RNA-seq and Proteomics.

Front Med (Lausanne). 2021 Nov 3;8:742436. doi: 10.3389/fmed.2021.742436. eCollection 2021.

Beneficial Extracardiac Effects of Cardiovascular Medications.

Curr Cardiol Rev. 2022;18(2):e151021197270. doi: 10.2174/1573403X17666211015145132.

Nitrosative Stress and Human Disease: Therapeutic Potential of Denitrosylation.

Int J Mol Sci. 2021 Sep 10;22(18):9794. doi: 10.3390/ijms22189794.

PDE9A deficiency does not prevent chronic-hypoxic pulmonary hypertension in mice.

Physiol Rep. 2021 Sep;9(18):e15057. doi: 10.14814/phy2.15057.

Integrated bioinformatic analysis reveals the underlying molecular mechanism of and potential drugs for pulmonary arterial hypertension.

Aging (Albany NY). 2021 May 18;13(10):14234-14257. doi: 10.18632/aging.203040.

The Efficacy and Safety of Pulmonary Vasodilators in Pediatric Pulmonary Hypertension (PH): A Systematic Review and Meta-analysis.

Front Pharmacol. 2021 Apr 23;12:668902. doi: 10.3389/fphar.2021.668902. eCollection 2021.